Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Warning! GuruFocus has detected 6 Warning Signs with ORCL. As of 2025-02-25, Eli Lilly and Co's intrinsic value as calculated by the Discounted Earnings model is $271.69. It's currently trading at ...

Lilly looks poised to hit a $1 trillion market value Shares of Eli Lilly haven't been doing well in recent months, but over the long run, I think they will more than recover. This is a company ...

The stock has more than doubled in value in the last two years, making it the most valuable healthcare company in the world, but has been subdued since October when Lilly reported disappointing ...

The bottom line: We're raising our Lilly fair value estimate to $620 from $580 to account for higher long-term growth from the oncology and immunology portfolio, which supports the firm's wide ...

When value trading, my threshold for a Buy rating is now an annual return expectation of 22.5%, and the price for Eli Lilly has risen 10% already since my last analysis in January. However ...